<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865187</url>
  </required_header>
  <id_info>
    <org_study_id>Lindheim2016-01</org_study_id>
    <nct_id>NCT02865187</nct_id>
  </id_info>
  <brief_title>Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction</brief_title>
  <acronym>Vit-D/PCOS</acronym>
  <official_title>Evaluation of Vitamin D With and Without Hormonal Contraception on Sexual Function in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wright State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patty Brisben Foundation For Women's Sexual Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wright State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SUMMARY:&#xD;
&#xD;
      Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age&#xD;
      women with a prevalence as high as 15%. The clinical symptoms of PCOS including menstrual&#xD;
      dysfunction, infertility, hirsutism, alopecia, acne, and the possible increased risk of&#xD;
      diabetes and cardiovascular disease have been reported to be significant contributors to&#xD;
      psychological morbidity and impact health-related quality of life. For women with PCOS, the&#xD;
      changes in physical appearance and the associated mood disorders appear to be deleterious for&#xD;
      sexual function.&#xD;
&#xD;
      Vitamin D deficiency (&lt;20 ng/ml serum concentration of 25[OH]D), which affects from 67% to&#xD;
      85% of women,4 is closely linked to symptoms of PCOS. The main physiologic role of vitamin D&#xD;
      is to regulate calcium and phosphorus homeostasis and to promote bone health. Although there&#xD;
      has been an increase in awareness of the importance of sexual dysfunction and QoL in women&#xD;
      with PCOS, few studies have evaluated the outcomes of treatment for PCOS upon sexual and&#xD;
      subjective health status of women.&#xD;
&#xD;
      The goals of this study are:&#xD;
&#xD;
        1. To evaluate the prevalence of sexual dysfunction (SDy) in women with Polycystic Ovarian&#xD;
           Syndrome (PCOS)&#xD;
&#xD;
        2. To determine the effects of Vitamin D therapy, with and without hormonal contraceptives,&#xD;
           on SDy in women with PCOS in the absence of depression.&#xD;
&#xD;
      METHODS:&#xD;
&#xD;
      The study will enroll 60 women diagnosed with PCOS and reporting SDy at the Wright State&#xD;
      Physicians (WSP) OB-GYN Practice and the WSP Family Medicine Practice.&#xD;
&#xD;
      All participants will take vitamin D 600IU/day and will choose between hormonal and&#xD;
      non-hormonal contraceptive methods (target of 30 participants in each group). Participants&#xD;
      will complete three study visits (Initial, Month 3, and Month 6). Vitamin D levels will be&#xD;
      drawn at the beginning of the study and again at 3 and 6 months after initiation of vitamin D&#xD;
      therapy. Each participant will be asked to complete the Female Sexual Function Index (FSFI)&#xD;
      and the Beck Depression Inventory (BDI) prior to initiation of treatment and again at 6&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age&#xD;
      women with a prevalence as high as 15% using Rotterdam diagnostic criteria.1 PCOS is a&#xD;
      heterogeneous clinical disorder characterized primarily by chronic anovulation and&#xD;
      hyperandrogenism.2 A number of other metabolic and health complications are associated with&#xD;
      PCOS including obesity, insulin resistance, dyslipidemia, type 2 diabetes, cardiovascular&#xD;
      disease, and endometrial cancer.3&#xD;
&#xD;
      The clinical symptoms of PCOS including menstrual dysfunction, infertility, hirsutism,&#xD;
      alopecia, acne, and the possible increased risk of diabetes and cardiovascular disease have&#xD;
      been reported to be significant contributors to psychological morbidity and impact&#xD;
      health-related quality of life (HRQoL)4,5 including depression and anxiety,6,7 suicide&#xD;
      attempts,8 body dissatisfaction,9 eating disorders,10 lower overall health-related quality of&#xD;
      life11 and diminished sexual satisfaction.12,13&#xD;
&#xD;
      For women with PCOS, the changes in physical appearance and the associated mood disorders&#xD;
      appear to be deleterious for sexual function.6 Previous research in this area is scant, and&#xD;
      what has been done reveals a large number of women with PCOS (60%) reporting sexual&#xD;
      dysfunction and that the domains of desire and arousal are most commonly affected (in 98% -&#xD;
      99% of cases). Using the Changes in Sexual Functioning Questionnaire (CSFQ), others have&#xD;
      reported that women with PCOS were similar to control women in the number of sexual thoughts&#xD;
      and fantasies and in the frequency of sexual intercourse, but differed significantly with&#xD;
      lower orgasm/completion scores than control women.13 The existing research is limited by the&#xD;
      study populations used, which have consisted of infertile women with PCOS who have a high&#xD;
      prevalence of sexual dysfunction that may be more related to infertility and not an&#xD;
      underlying sexual dysfunction, and by the possible impact of depression and psychotropic&#xD;
      medications on sexual dysfunction.&#xD;
&#xD;
      Vitamin D deficiency (&lt;20 ng/ml serum concentration of 25[OH]D), which affects from 67% to&#xD;
      85% of women,4 is closely linked to symptoms of PCOS. Observational studies have shown that&#xD;
      lower 25[OH]D levels are associated with insulin resistance, ovulatory and menstrual&#xD;
      irregularities, lower pregnancy success, hirsutism, hyperandrogenism, obesity, and elevated&#xD;
      cardiovascular disease risk factors14 as well as decreased HRQoL and depression in select&#xD;
      populations.15 Nonetheless, there is limited research exploring the implications of vitamin D&#xD;
      status and replacement on HRQoL issues including SDy.&#xD;
&#xD;
      The main physiologic role of vitamin D is to regulate calcium and phosphorus homeostasis and&#xD;
      to promote bone health. However, accumulating evidence suggests that vitamin D deficiency may&#xD;
      also be an important factor for many other diseases. Several mechanisms of action have been&#xD;
      proposed to explain the association between vitamin D and depression.&#xD;
&#xD;
      The role of calcitriol or 1,25 dihydroxy cholecalciferol, the bioactive form of vitamin D, in&#xD;
      brain tissue has been confirmed by the presence of vitamin D receptors (VDRs) and&#xD;
      hydroxylases in various brain regions. One area where VDRs and hydroxylases have been found&#xD;
      in the amygdala, the center of the limbic system, where behavior and emotions are&#xD;
      regulated.16 In addition, Vitamin D is involved in numerous brain processes including&#xD;
      neuroimmunomodulation, regulation of neurotrophic factors, neuroprotection, neuroplasticity&#xD;
      and brain development,16 making it biologically plausible that vitamin D might be associated&#xD;
      with HRQoL and SDy.&#xD;
&#xD;
      Although there has been an increase in awareness of the importance of sexual dysfunction and&#xD;
      QoL in women with PCOS, few studies have evaluated the outcomes of treatment for PCOS upon&#xD;
      sexual and subjective health status of women. Therapy has been directed at treating the&#xD;
      physical symptoms produced by chronic anovulation, hyperandrogenism and metabolic&#xD;
      disturbances associated with insulin resistance of PCOS. Treatment for PCOS has included oral&#xD;
      hypoglycemic agents, laparoscopic wedge resection, and cosmetic procedures, such as laser&#xD;
      hair removal, but the mainstay remains combined hormonal contraception.&#xD;
&#xD;
      The specific contribution of estrogens and progestogens in oral contraceptives is not fully&#xD;
      understood, particularly the latter as it has variable potency and androgenicity. In general,&#xD;
      the most commonly used progestins are the 19-testosterone derivatives. Newer oral&#xD;
      contraceptives, such as drospirenone, norgestimate, and desogestrel, contain less androgenic&#xD;
      progestins. Drospirenone is a 17-alpha spironolactone derivative progestin with&#xD;
      antiandrogenic and antimineralocorticoid activity. Studies have shown various benefits of&#xD;
      combined hormonal contraceptives for PCOS patients who are not pursuing fertility, e.g.,&#xD;
      management of endocrine and metabolic profiles, androgen levels, and endometrial cancer.5&#xD;
&#xD;
      Vitamin D supplementation has also been reported to improve glucose metabolism and menstrual&#xD;
      frequency in PCOS women17 and since Vitamin D deficiency is closely linked to PCOS and&#xD;
      depression, its supplementation has been suggested to possibly play an important part in the&#xD;
      treatment of PCOS and HRQoL and perhaps SDy.18&#xD;
&#xD;
      As such, the goal of this study is to evaluate the prevalence of sexual dysfunction and&#xD;
      assess the impact of treatment using oral contraceptives with Vitamin D on SDy in absence of&#xD;
      depression. The investigators anticipate this may provide a new treatment strategy in SDy&#xD;
      issues for women with PCOS.&#xD;
&#xD;
      METHODS:&#xD;
&#xD;
      The study will enroll 60 women diagnosed with PCOS and reporting SDy at the Wright State&#xD;
      Physicians (WSP) OB-GYN Practice and the WSP Family Medicine Practice.&#xD;
&#xD;
      All participants will take vitamin D 600IU/day (as recommended by the National Institutes of&#xD;
      Health's Office of Dietary Supplements) and will choose between hormonal and non-hormonal&#xD;
      contraceptive methods (target of 30 participants in each group). Participants will complete&#xD;
      three study visits (Initial, Month 3, and Month 6). Vitamin D levels will be drawn at the&#xD;
      beginning of the study and again at 3 and 6 months after initiation of vitamin D therapy.&#xD;
      Each participant will be asked to complete the Female Sexual Function Index (FSFI) and the&#xD;
      Beck Depression Inventory (BDI) prior to initiation of treatment and again at 6 months.&#xD;
&#xD;
      HUMAN SUBJECTS PROTECTION:&#xD;
&#xD;
      The PI is responsible for protection of human subjects. This protocol will be reviewed by the&#xD;
      WSU Institutional Review Board. Only subjects who meet study eligibility criteria will be&#xD;
      enrolled. All eligible participants will have the study explained to them. The informed&#xD;
      consent process will be conducted appropriately and the informed consent will be obtained&#xD;
      prior to proceeding with any study procedures.&#xD;
&#xD;
      The primary physician or the Principal Investigator and research associates will be the&#xD;
      individuals obtaining informed consent from patients. They will be uniform in their&#xD;
      explanations of the nature of the study to all patients who fit the selection criteria. Those&#xD;
      patients interested in participating will be given time to read over the informed consent.&#xD;
      The patients will be asked either in the clinic to be involved in the study. After the&#xD;
      informed consent is reviewed by the patient any remaining questions will be answered.&#xD;
&#xD;
      Adverse events will be reviewed and evaluated by the PI throughout the study. In the event&#xD;
      that any additional diagnoses are obtained during this study, the primary physician for the&#xD;
      patient will be notified. It will be their responsibility to notify the patient of these&#xD;
      diagnoses and any changes to management that may result.&#xD;
&#xD;
      Subjects' confidentiality will be protected. Participants will be assigned a unique&#xD;
      identification (ID) number for the study that will be used on data collection forms rather&#xD;
      than subjects' names. Only the minimum data necessary to conduct the study and meet the&#xD;
      objectives will be collected. Data will be stored in a secure database (REDCap19) that uses a&#xD;
      unique username and password for each team member. Data will be de-identified prior to&#xD;
      analysis.&#xD;
&#xD;
      SIGNIFICANCE OF THE STUDY IN RELATION TO HUMAN HEALTH (BENEFITS):&#xD;
&#xD;
      PCOS is the most common reproductive endocrine disorder that has a number of health quality&#xD;
      of life issues. The benefit of this study will be to identify SDy which is often overlooked&#xD;
      and may potentially be helped with Vit D and/or birth control.&#xD;
&#xD;
      POTENTIAL HAZARDS (RISKS):&#xD;
&#xD;
      The study questionnaires may evoke stressful feelings taking a psychosocial questionnaire. In&#xD;
      addition, there are rare potential risks related to OCPs including deep venous thrombosis,&#xD;
      and stroke.&#xD;
&#xD;
      Serious side effects of vitamin D include allergic reactions, swelling of the face, throat,&#xD;
      and tongue, dizziness, irregular or racing heart beat, dry mouth, headache, vomiting,&#xD;
      weakness and lack of energy, and fatigue&#xD;
&#xD;
      The risks of taking blood include pain, a bruise at the point where the blood is taken,&#xD;
      redness and swelling of the vein and infection, and a rare risk of fainting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual Function</measure>
    <time_frame>Month 6</time_frame>
    <description>Female Sexual Function Index (FSFI) scores at Month 6 (Total score ranges from 2 - 36; scores less than 26.55 represent presence/degree of sexual dysfunction)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Sexual Dysfunction in Women With PCOS</measure>
    <time_frame>Baseline</time_frame>
    <description>Prevalence rate of women with PCOS defined by scores of the FSFI (total scores range from 2-36; scores less than 26.55 represent presence/degree of sexual dysfunction) - For this outcome, total scores were converted, using the cutoff score of 26.55, into a dichotomous variable for presence or absence of sexual dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Female Sexual Dysfunction</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Vitamin D + hormonal contraception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600IU/day Vitamin D + hormonal contraception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit D + non-hormonal contraception</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600IU/day Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D 600IU/day</description>
    <arm_group_label>Vit D + non-hormonal contraception</arm_group_label>
    <arm_group_label>Vitamin D + hormonal contraception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormonal contraception</intervention_name>
    <description>Hormonal contraceptives</description>
    <arm_group_label>Vitamin D + hormonal contraception</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Reproductive age&#xD;
&#xD;
          -  2. Have diagnosis of polycystic ovary syndrome by Rotterdam criteria (at least 2 of 3&#xD;
             criteria):&#xD;
&#xD;
          -  a. Oligomenorrhea (cycles lasting &gt; 35 days) or amenorrhea (&lt; 3 cycles in last 6&#xD;
             months)&#xD;
&#xD;
          -  b. Clinical signs of hyperandrogenism or elevated total testosterone level&#xD;
&#xD;
          -  c. Polycystic appearing ovaries&#xD;
&#xD;
          -  3. Report sexual dysfunction&#xD;
&#xD;
          -  4. Have no evidence of depression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Has chronic medical illness such as diabetes mellitus, hypertension, and previous&#xD;
             venous embolism&#xD;
&#xD;
          -  2. Taking any prescription medications for at least 3 months prior to entry into the&#xD;
             study with the exception of allergy or occasional pain medications&#xD;
&#xD;
          -  3. Has other etiologies of anovulation and hyperandrogenism, e.g., Cushings disease,&#xD;
             thyroid dysfunction, elevated prolactin levels, sighs of congenital adrenal&#xD;
             hyperplasia&#xD;
&#xD;
          -  4. Has any contraindications to hormonal contraception&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Lindheim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.</citation>
    <PMID>14711538</PMID>
  </reference>
  <reference>
    <citation>Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007 Aug 25;370(9588):685-97. Review.</citation>
    <PMID>17720020</PMID>
  </reference>
  <reference>
    <citation>Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9.</citation>
    <PMID>15181052</PMID>
  </reference>
  <reference>
    <citation>McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2005 Jan-Feb;34(1):12-20.</citation>
    <PMID>15673641</PMID>
  </reference>
  <reference>
    <citation>Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007 Aug;22(8):2279-86. Epub 2007 May 30.</citation>
    <PMID>17537782</PMID>
  </reference>
  <reference>
    <citation>Gorwood P. Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? Eur Psychiatry. 2004 Feb;19(1):27-33. Review.</citation>
    <PMID>14969778</PMID>
  </reference>
  <reference>
    <citation>Månsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landén M. Women with polycystic ovary syndrome are often depressed or anxious--a case control study. Psychoneuroendocrinology. 2008 Sep;33(8):1132-8. doi: 10.1016/j.psyneuen.2008.06.003. Epub 2008 Jul 30.</citation>
    <PMID>18672334</PMID>
  </reference>
  <reference>
    <citation>Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009 Jan;91(1):207-12. doi: 10.1016/j.fertnstert.2007.11.022. Epub 2008 Feb 4.</citation>
    <PMID>18249398</PMID>
  </reference>
  <reference>
    <citation>McCluskey SE, Lacey JH, Pearce JM. Binge-eating and polycystic ovaries. Lancet. 1992 Sep 19;340(8821):723.</citation>
    <PMID>1355813</PMID>
  </reference>
  <reference>
    <citation>Naessén S, Carlström K, Garoff L, Glant R, Hirschberg AL. Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria. Gynecol Endocrinol. 2006 Jul;22(7):388-94.</citation>
    <PMID>16864149</PMID>
  </reference>
  <reference>
    <citation>Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf). 2007 Mar;66(3):373-9.</citation>
    <PMID>17302871</PMID>
  </reference>
  <reference>
    <citation>Janssen OE, Hahn S, Tan S, Benson S, Elsenbruch S. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med. 2008 Jan;26(1):45-52. doi: 10.1055/s-2007-992924. Review.</citation>
    <PMID>18181082</PMID>
  </reference>
  <reference>
    <citation>Stovall DW, Scriver JL, Clayton AH, Williams CD, Pastore LM. Sexual function in women with polycystic ovary syndrome. J Sex Med. 2012 Jan;9(1):224-30. doi: 10.1111/j.1743-6109.2011.02539.x. Epub 2011 Nov 14.</citation>
    <PMID>22082203</PMID>
  </reference>
  <reference>
    <citation>Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012 Sep;77(3):343-50. doi: 10.1111/j.1365-2265.2012.04434.x. Review.</citation>
    <PMID>22574874</PMID>
  </reference>
  <reference>
    <citation>Gur EB, Gokduman A, Turan GA, Tatar S, Hepyilmaz I, Zengin EB, Eskicioglu F, Guclu S. Mid-pregnancy vitamin D levels and postpartum depression. Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:110-6. doi: 10.1016/j.ejogrb.2014.05.017. Epub 2014 Jun 2.</citation>
    <PMID>24965990</PMID>
  </reference>
  <reference>
    <citation>Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S265-77. doi: 10.1016/j.psyneuen.2009.05.023. Review.</citation>
    <PMID>19545951</PMID>
  </reference>
  <reference>
    <citation>Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest. 2011 Nov;34(10):757-63. doi: 10.3275/7748. Epub 2011 May 24.</citation>
    <PMID>21613813</PMID>
  </reference>
  <reference>
    <citation>Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry. 2013 Feb;202:100-7. doi: 10.1192/bjp.bp.111.106666. Review.</citation>
    <PMID>23377209</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <results_first_submitted>July 28, 2020</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wright State University</investigator_affiliation>
    <investigator_full_name>Steven Lindheim, MD</investigator_full_name>
    <investigator_title>Professor, Director Reproductive Endocrinology and Infertility</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>polycystic ovary syndrome</keyword>
  <keyword>polycystic ovarian syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>sexual dysfunction</keyword>
  <keyword>female sexual dysfunction</keyword>
  <keyword>low libido</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02865187/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02865187/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D + Hormonal Contraception</title>
          <description>600IU/day Vitamin D + hormonal contraception&#xD;
Vitamin D: Vitamin D 600IU/day&#xD;
Hormonal contraception: Hormonal contraceptives</description>
        </group>
        <group group_id="P2">
          <title>Vit D + Non-hormonal Contraception</title>
          <description>600IU/day Vitamin D&#xD;
Vitamin D: Vitamin D 600IU/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2 - at 3 Months</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D + Hormonal Contraception</title>
          <description>600IU/day Vitamin D + hormonal contraception&#xD;
Vitamin D: Vitamin D 600IU/day&#xD;
Hormonal contraception: Hormonal contraceptives</description>
        </group>
        <group group_id="B2">
          <title>Vit D + Non-hormonal Contraception</title>
          <description>600IU/day Vitamin D&#xD;
Vitamin D: Vitamin D 600IU/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="5.6"/>
                    <measurement group_id="B2" value="32.2" spread="5.1"/>
                    <measurement group_id="B3" value="29.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Sexual Function Inventory (FSFI)</title>
          <description>Total FSFI score ranges from 2-36. Scores below 26.55 indicate presence and degree of sexual dysfunction.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="8.3"/>
                    <measurement group_id="B2" value="22.8" spread="4.6"/>
                    <measurement group_id="B3" value="20.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sexual Function</title>
        <description>Female Sexual Function Index (FSFI) scores at Month 6 (Total score ranges from 2 - 36; scores less than 26.55 represent presence/degree of sexual dysfunction)</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D + Hormonal Contraception</title>
            <description>600IU/day Vitamin D + hormonal contraception&#xD;
Vitamin D: Vitamin D 600IU/day&#xD;
Hormonal contraception: Hormonal contraceptives</description>
          </group>
          <group group_id="O2">
            <title>Vit D + Non-hormonal Contraception</title>
            <description>600IU/day Vitamin D&#xD;
Vitamin D: Vitamin D 600IU/day</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Function</title>
          <description>Female Sexual Function Index (FSFI) scores at Month 6 (Total score ranges from 2 - 36; scores less than 26.55 represent presence/degree of sexual dysfunction)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="7.6"/>
                    <measurement group_id="O2" value="26.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>a priori threshold for significance was set at p&lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Sexual Dysfunction in Women With PCOS</title>
        <description>Prevalence rate of women with PCOS defined by scores of the FSFI (total scores range from 2-36; scores less than 26.55 represent presence/degree of sexual dysfunction) - For this outcome, total scores were converted, using the cutoff score of 26.55, into a dichotomous variable for presence or absence of sexual dysfunction.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D + Hormonal Contraception</title>
            <description>600IU/day Vitamin D + hormonal contraception&#xD;
Vitamin D: Vitamin D 600IU/day&#xD;
Hormonal contraception: Hormonal contraceptives</description>
          </group>
          <group group_id="O2">
            <title>Vit D + Non-hormonal Contraception</title>
            <description>600IU/day Vitamin D&#xD;
Vitamin D: Vitamin D 600IU/day</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Sexual Dysfunction in Women With PCOS</title>
          <description>Prevalence rate of women with PCOS defined by scores of the FSFI (total scores range from 2-36; scores less than 26.55 represent presence/degree of sexual dysfunction) - For this outcome, total scores were converted, using the cutoff score of 26.55, into a dichotomous variable for presence or absence of sexual dysfunction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>a priori threshold for significance was set at p&lt; 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Chi square</param_type>
            <param_value>.000</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D + Hormonal Contraception</title>
          <description>600IU/day Vitamin D + hormonal contraception&#xD;
Vitamin D: Vitamin D 600IU/day&#xD;
Hormonal contraception: Hormonal contraceptives</description>
        </group>
        <group group_id="E2">
          <title>Vit D + Non-hormonal Contraception</title>
          <description>600IU/day Vitamin D&#xD;
Vitamin D: Vitamin D 600IU/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Participants were allowed to choose their treatment group. There was a large number of lost to follow-up participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven R Lindheim</name_or_title>
      <organization>Wright State University</organization>
      <phone>858-740-1083</phone>
      <email>doclalalindheim@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

